Race Executes Contracts to Commence Breast Cancer Trial
Summary
<p class="typography-body-regular">Contract Research Organisations Resolutum Global, Beyond Drug Development, and NSW Regional Biospecimen & Research Services have been appointed to support the Zantrene breast cancer cardioprotection clinical program. </p>
<p class="typography-body-regular"><br></p>
<p class="typography-body-regular">Clinical trial institutional governance submission is expected soon and will enable enrolment of the first study patient.</p>
<p class="typography-body-regular"><br></p>
<p class="typography-body-regular">This observation trial will place a spotlight on the irreversible damage to the heart that can be induced by AC chemotherapy and is the first step in advancing the Zantrene cardioprotection opportunity in the clinic. </p>
Your question will be sent privately to Racura Oncology. The company may choose to make this question public.
Start the conversation
Ask Racura Oncology a question about this announcement.
Share your feedback
Discover